New drug targets immune system to tame arthritis

NCT ID NCT07433335

Recruiting now Disease control Sponsor: SciRhom GmbH Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new medicine called SR-878 in 27 adults with rheumatoid arthritis. The drug works by blocking a protein that controls immune signals. The main goal is to check safety and find a good dose. Participants will be followed for about 16 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SR-878
What this could lead to: If it works, this could point toward a new treatment for rheumatoid arthritis by calming the immune system.
What could go wrong: This is a very early Phase 1 safety study with only 27 people. It is too small to prove effectiveness, and the drug may cause side effects or fail in later trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEUMATOID ARTHRITIS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

SciRhom clinical trial site
RECRUITING

Tbilisi, Georgia
SciRhom clinical trial site
RECRUITING

Chisinau, Moldova
SciRhom clinical trial site
RECRUITING

Bucharest, Romania
SciRhom clinical trial site
RECRUITING

Cluj-Napoca, Romania

More trials for these conditions

Other studies related to the condition(s) this trial covers.